AAM opposes latest prescription drug reform framework
WASHINGTON — In response to press reports on the current framework on prescription drug policies, AAM and its Biosimilars Council issued the following statement on the potential impact to patient access to generic and biosimilar medicines: “Patient access to more affordable generic and biosimilar medicines would be threatened under the policies currently under consideration in
